Evaluation of the Duration of Action and Comparative Effectiveness of Lisdexamfetamine Dimesylate and Behavioral Treatment in Youth With ADHD in a Quasi-Naturalistic Setting

Abstract

Objective: This study compared the relative effects of three treatment conditions: long-acting stimulant medication (MED), behavior modification, and medication/behavioral treatments combined (COM) in children with ADHD. Method: A total of 25 children, aged 6 to 12 years, received the three treatment conditions during a 7-week Summer Treatment Program in an alternating treatments design. Counselors completed behavioral ratings from 0.5 to 12.5 hr post dose, and parents completed nighttime ratings. Results: Ratings for SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham) and for following instructions indicated COM and MED improved symptoms over BEH treatment beginning 3 hr post dose (p = .008), with ratings maintained 12.5 hr post dose (p = .001 and .006). Results for frustration tolerance indicated significant improvement in all three conditions until 9 hr post dose. Conclusion: MED and COM separated from BEH at 3 hr post dose, and sustained benefit was observed across the day for two of three measures. BEH appears to have an additive effect, extending the duration of frustration tolerance.

Keywords

ADHD psychosocial treatment multimodal treatment extended-release stimulant medication

Get full access to this article

View all access options for this article.

References

Adesman

A. R.

(2001). The diagnosis and management of attention-deficit/hyperactivity disorder in pediatric patients. Primary Care Companion to the Journal of Clinical Psychiatry, 3, 66-77.

American Academy of Pediatrics, Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. (2001). Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics, 108, 1033-1044.

American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.

Barkley

R. A.

(1997). Behavioral inhibition, sustained attention, and executive functions: Constructing a unifying theory of ADHD. Psychological Bulletin, 121, 65-94.

Baumeister

R. F.

Bratslavsky

Muraven

Tice

D. M.

(1998). Ego depletion: Is the active self a limited resource? Journal of Personality and Social Psychology, 74, 1252-1265.

Biederman

(1998). Attention-deficit/hyperactivity disorder: A life-span perspective. Journal of Clinical Psychiatry, 59(Suppl. 7), 4-16.

Biederman

(2005). Attention-deficit/hyperactivity disorder: A selective overview. Biological Psychiatry, 57, 1215-1220.

Biederman

Boellner

S. W.

Childress

Lopez

F. A.

Krishnan

Zhang

(2007). Lisdexamfetamine dimesylate and mixed amphetamine salts extended-release in children with ADHD: A double-blind, placebo-controlled, crossover analog classroom study. Biological Psychiatry, 62, 970-976.

Biederman

Faraone

Milberger

Guite

Mick

Chen

(1996). A prospective 4-year follow-up study of attention-deficit hyperactivity and related disorders. Archives of General Psychiatry, 53, 437-446.

10.

Biederman

Krishnan

Zhang

McGough

J. J.

Findling

R. L.

(2007). Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: A phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clinical Therapeutics, 29, 450-463.

11.

Biederman

Newcorn

Sprich

(1991). Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. American Journal of Psychiatry, 148, 564-577.

12.

Centers for Disease Control and Prevention. (2010). Increasing prevalence of parent-reported attention-deficit/hyperactivity disorder among children—United States, 2003 and 2007. MMWR. Morbidity and Mortality Weekly Report, 59, 1439-1443.

13.

Chronis

A. M.

Fabiano

G. A.

Gnagy

E. M.

Onyango

A. N.

Pelham

W. E.

Lopez-Williams

Seymour

K. E.

(2004). An evaluation of the Summer Treatment Program for children with attention-deficit/hyperactivity disorder using a treatment withdrawal design. Behavior Therapy, 35, 561-585.

14.

DuPaul

G. J.

Power

T. J.

McGoey

K. E.

Ikeda

M. J.

Anastopoulos

A. D.

(1998). Reliability and validity of parent and teacher ratings of attention-deficit hyperactivity disorder symptoms. Journal of Psychoeducational Assessment, 16, 55-68.

15.

Findling

R. L.

Childress

A. C.

Krishnan

McGough

J. J.

(2008). Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. CNS Spectrums, 13, 614-620.

16.

Frazier

T. W.

Weiss

Hodgkins

Manos

M. J.

Landgraf

J. M.

Gibbins

(2010). Time course and predictors of health-related quality of life improvement and medication satisfaction in children diagnosed with attention-deficit/hyperactivity disorder treated with the methylphenidate transdermal system. Journal of Child and Adolescent Psychopharmacology, 20, 355-364.

17.

Gartlehner

Hansen

R. A.

Nissman

Lohr

K. N.

Carey

T. S.

(2006). A simple and valid tool distinguished efficacy from effectiveness studies. Journal of Clinical Epidemiology, 59, 1040-1048.

18.

Hersen

Barlow

(1976). Single-case experimental designs: Strategies for studying behavior change. New York, NY: Pergamon.

19.

Inzlicht

Gutsell

J. N.

(2007). Running on empty: Neural signals for self-control failure. Psychological Science, 18, 933-937.

20.

Jensen

P. S.

(2001). Introduction—ADHD comorbidity and treatment outcomes in the MTA. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 134-136.

21.

Johnston

Mash

E. J.

(2001). Families of children with attention-deficit/hyperactivity disorder: Review and recommendations for future research. Clinical Child and Family Psychology Review, 4, 183-207.

22.

Kaplan

Newcorn

J. H.

(2011). Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder. Pediatric Clinics of North America, 58, 99-120, xi.

23.

Kazdin

A. E.

(1982). Single-case research designs. New York, NY: Oxford University Press.

24.

Limbers

C. A.

Ripperger-Suhler

Boutton

Ransom

Varni

J. W.

(2010). A comparative analysis of health-related quality of life and family impact between children with ADHD treated in a general pediatric clinic and a psychiatric clinic utilizing the PedsQL. Journal of Attention Disorders, 15, 392-402.

25.

Manos

M. J.

Short

E. J.

Findling

R. L.

(1999). Differential effectiveness of methylphenidate and Adderall in school-age youths with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 38, 813-819.

26.

March

J. S.

Swanson

J. M.

Arnold

L. E.

Hoza

Conners

C. K.

Hinshaw

S. P.

Pelham

W. E.

(2000). Anxiety as a predictor and outcome variable in the Multimodal Treatment Study of Children With ADHD (MTA). Journal of Abnormal Child Psychology, 28, 527-541.

27.

McGonigle

J. J.

Rojahn

Dixon

Strain

P. S.

(1987). Multiple treatment interference in the alternating treatments design as a function of the intercomponent interval length. Journal of Applied Behavior Analysis, 20, 171-178.

28.

Molina

B. S.

Hinshaw

S. P.

Swanson

J. M.

Arnold

L. E.

Vitiello

Jensen

P. S.

MTA Cooperative Group . (2009). The MTA at 8 years: Prospective follow-up of children treated for combined-type ADHD in a multisite study. Journal of the American Academy of Child & Adolescent Psychiatry, 48, 484-500.

29.

MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children With ADHD. Archives of General Psychiatry, 56, 1073-1086.

30.

Murray

D. W.

Bussing

Fernandez

Hou

Garvan

C. W.

Swanson

J. M.

Eyberg

S. M.

(2009). Psychometric properties of teacher SKAMP ratings from a community sample. Assessment, 16, 193-208.

31.

Pelham

W. E.

Burrows-Maclean

Gnagy

E. M.

Fabiano

G. A.

Coles

E. K.

Tresco

K. E.

Hoffman

M. T.

(2005). Transdermal methylphenidate, behavioral, and combined treatment for children with ADHD. Experimental and Clinical Psychopharmacology, 13, 111-126.

32.

Pelham

W. E.

Greiner

Gnagy

(1998). Summer Treatment Program manual. Buffalo, NY: Comprehensive Treatment for Attention Deficit Disorders.

33.

Pelham

W. E.

Hoza

(1996). Intensive treatment: A Summer Treatment Program for children with ADHD. In Hibbs

Jensen

(Eds.), Psychosocial treatments for child and adolescent disorders: Empirically based strategies for clinical practice (pp. 311-340). New York, NY: APA Press.

34.

Peugh

J. L.

Enders

C. K.

(2005). Using the SPSS mixed procedure to fit cross-sectional and longitudinal multilevel models. Educational and Psychological Measurement, 65, 717-741.

35.

Pliszka

, & AACAP Work Group on Quality Issues. (2007). Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 894-921.

36.

Pliszka

S. R.

Crismon

M. L.

Hughes

C. W.

Conners

C. K.

Emslie

G. J.

Jensen

P. S.

Texas Consensus Conference Panel on Pharmacotherapy of Childhood Attention Deficit Hyperactivity Disorder. (2006). The Texas Children’s Medication Algorithm Project: Revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 642-657.

37.

Spencer

T. J.

Biederman

Mick

(2007). Attention-deficit/hyperactivity disorder: Diagnosis, lifespan, comorbidities, and neurobiology. Journal of Pediatric Psychology, 32, 631-642.

38.

Swensen

A. R.

Birnbaum

H. G.

Secnik

Marynchenko

Greenberg

Claxton

(2003). Attention-deficit/ hyperactivity disorder: Increased costs for patients and their families. Journal of the American Academy of Child & Adolescent Psychiatry, 42, 1415-1423.

39.

Tabachnick

B. G.

Fidell

L. S.

(2007). Multilevel linear modeling. In Using multivariate statistics (5th ed., pp. 781-857). Boston, MA: Pearson / Allyn & Bacon.

40.

Van der Oord

Prins

P. J.

Oosterlaan

Emmelkamp

P. M.

(2008). Efficacy of methylphenidate, psychosocial treatments and their combination in school-aged children with ADHD: A meta-analysis. Clinical Psychology Review, 28, 783-800.

41.

Vaughan

B. S.

March

J. S.

Kratochvil

C. J.

(2011). The evidence-based pharmacological treatment of paediatric ADHD. International Journal of Neuropsychopharmacology, 14, 1-13.

42.

Wigal

S. B.

Gupta

Guinta

Swanson

J. M.

(1998). Reliability and validity of the SKAMP rating scale in a laboratory school setting. Psychopharmacology Bulletin, 34, 47-53.

43.

Wigal

S. B.

Kollins

S. H.

Childress

A. C.

Squires

, & 311 Study Group. (2009). A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child & Adolescent Psychiatry & Mental Health, 3, 17.